In samples obtained from e-PE after the onset of clinical signs, circulating levels of EGFL7 were significantly increased at 22–25 weeks of gestation compared to both isolated IUGR and controls (69.86 ± 6.17 μg/ml, 18.8 ± 2.8 μg/ml and 19.8 ± 2.5 μg/ml, respectively; Fig. 1A). This evidence concerns the gene EGFL7 and fetal growth restriction.